Options for surgical management of IFIS are multiple

Article

Several options are available to cataract surgeons to manage anticipated IFIS. In the multicenter prospective trial, surgeons could use a mechanical restraining device (iris expansion ring or iris retractors) to enlarge the pupil and keep the iris from prolapsing, viscodilation with Healon 5 (Advanced Medical Optics), or pharmacologic intervention with atropine administered three times daily beginning 2 days before surgery.

Several options are available to cataract surgeons to manage anticipated IFIS. In the multicenter prospective trial, surgeons could use a mechanical restraining device (iris expansion ring or iris retractors) to enlarge the pupil and keep the iris from prolapsing, viscodilation with Healon 5 (Advanced Medical Optics), or pharmacologic intervention with atropine administered three times daily beginning 2 days before surgery.

Viscodilation should be combined with low-flow, low-vacuum surgery and can also be performed using DisCoVisc (Alcon Laboratories) as the ophthalmic viscosurgical device. Other techniques that have been reported successful include intraoperative mydriatic treatment with epinephrine injected under the iris, as described by Joel Saugar, MD, or with intraocular phenylephrine, as reported by Richard Packard, MD.

The prospective, multicenter study undertaken to characterize the safety of cataract surgery in patients taking tamsulosin using the various techniques was not intended to establish the superiority of any one strategy. As observed by Samuel Masket, MD, the clinical reality is that the various techniques should not be considered mutually exclusive, but rather as complementary.

Dr. Masket initiated the concept of using preoperative atropine, and he reported that he has accumulated a series of 20 patients at risk for IFIS in whom he has used it combined with intraocular epinephrine. In 19 eyes, the case proceeded uneventfully, while it was necessary also to place iris hooks to achieve adequate dilation in one patient who had a very small pupil.

Recent Videos
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
© 2024 MJH Life Sciences

All rights reserved.